$GSK

Hansoh Pharma: Phase III Trial For Ris-Rez Meets Primary Endpoint In China

Hansoh Pharmaceutical Group said its ARTEMIS-008 phase III trial of risvutatug rezetecan (Ris-Rez), a B7-H3 targeted ADC for advanced or relapsed small-cell lung cancer, met the primary endpoint of overall survival in China. GSK, which holds exclusive worldwide rights excluding China mainland, Hong Kong, Macau and Taiwan, said results support the target. GSK shares rose about 1% premarket to $53.01.

Original reporting
Published Jul 10, 2026, 1:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 10, 2026, 1:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefTechnology
Primary signal
$GSK
Bullish
medium confidence
Mentioned
$GSK
Relevance
7/10
alphai data visualization · based on rttnews.com
Decision brief

The 30-second read

$GSKBullishMed
01

Why it matters

Meeting the overall survival primary endpoint is a major clinical milestone and strengthens the probability of success for Ris-Rez, which is relevant to GSK because it has exclusive worldwide rights outside specified China regions.

02

Market read

Traders may reassess GSK’s oncology pipeline value and near-term sentiment toward B7-H3 ADCs after a positive Phase III overall survival readout.

03

What to watch

The article does not provide magnitude of benefit, statistical robustness, or safety/tolerability, which are key for valuation and regulatory confidence.

Relevance 7/10Novelty 7/10Timing: pre-market today after Phase III overall survival primary endpoint met

Background

ARTEMIS-008 is a Phase III trial of risvutatug rezetecan (Ris-Rez), a B7-H3 targeted ADC, in advanced or relapsed small-cell lung cancer.

Company-level read

Ticker impact

$GSKBullishMedium confidence
Context

Hansoh Pharma’s Phase III ARTEMIS-008 met overall survival in advanced small-cell lung cancer, and GSK holds exclusive rights to Ris-Rez outside China.

Expected impact

Near-term upside bias for GSK on trial success, with follow-through likely tied to confirmatory details and regulatory next steps.

Evidence & confidence

The article reports a primary endpoint win (overall survival) and notes GSK’s commercialization rights outside China, which directly links the data to GSK’s pipeline value.

Market effects

Adds incremental validation for B7-H3 as an ADC target in solid tumors, potentially improving sentiment toward similar oncology ADC programs.

GSK’s rights exclude mainland China, Hong Kong, Macau, and Taiwan, so upside may be more pronounced for ex-China commercialization expectations.

Phase III overall survival data can influence global ADC competitive positioning and partner/deal expectations for B7-H3 programs.

Counterpoint

Overall survival success may already be partially priced for ADCs; without effect size, hazard ratio, or safety details, the market may demand more before sustaining gains.

Key entities

  • GSK

    Licensor with exclusive worldwide rights (excluding mainland China, Hong Kong, Macau, Taiwan) to develop and commercialize Ris-Rez.

  • Hansoh Pharmaceutical Group

    Announced Phase III ARTEMIS-008 results for Ris-Rez meeting the overall survival primary endpoint.

  • ARTEMIS-008

    Phase III trial evaluating Ris-Rez in advanced or relapsed small-cell lung cancer.

Related articles

$GSKMed

Could GSK plc (GSK)’s Pipeline Acceleration Unlock a New Growth Era?

GSK plc reported Q2 results on July 28. Total turnover was £8.4bn, up 5% CER. Core operating profit rose 7% CER to £2.80bn and Core EPS increased 9% CER to 50.5p, driven by Specialty Medicines and Vaccines. Total operating profit fell 75% CER due to a £1.3bn non-cash impairment after discontinuing camlipixant. GSK also outlined a 2026 Phase III acceleration plan and a £1.9bn annual cost-savings restructuring program.

$GSKMed

GSK Share Price: Q2 Results, Cambridge R&D Investment

GSK plc shares traded around £19.18 on 10 Aug 2026 after its Q2 results on 28 Jul. The company reported turnover £8.41bn (+5%), core operating profit £2.80bn (+7%) and core EPS 50.5p (+9%), plus a £1.9bn cost-savings programme through 2029 and a £400m Cambridge R&D centre investment. Brokers’ 12-month targets ranged from £17 to £21.51.

$GSKMedAI 8/10

GSK Pharma Q1 Net Profit Jumps 16% To ₹237 Crore

GlaxoSmithKline Pharmaceuticals reported Q1 FY2026-27 net profit of ₹237.1 crore, up 15.7% from ₹205 crore a year earlier. Revenue from operations rose 16.6% to ₹938 crore. EBITDA increased 25.8% to ₹444.3 crore, lifting EBITDA margin to 47.35%. The company cited growth across medicines, respiratory, vaccines, and oncology, and noted plans for Blenrep and marketing authorization for Arexvy.

$GSKMedAI 8/10

GSK Pharma Q1 profit rises 16% as general medicines, vaccines drive growth

GSK plc subsidiary GSK Pharma reported June-quarter FY27 net profit of ₹237.1 crore, up 16% from ₹205 crore a year earlier. Revenue from operations rose 16.6% to ₹938 crore. EBITDA increased 25.8% to ₹444.3 crore and margin to 47.35%. Growth was driven by general medicines and vaccines; oncology and pipeline launches were also cited.

$GSKMed

GSK India Q1FY27 PAT rises 24% to ₹253 crore on portfolio strength

GlaxoSmithKline Pharmaceuticals India reported Q1FY27 standalone PAT up 24% to ₹253 crore and revenue up 15% to ₹924 crore, ended June 30, 2026, citing portfolio transformation and base effects. Consolidated net profit rose 15.7% to ₹2,371.8 crore and revenue grew 16.5% to ₹9,384.4 crore. The board approved results Aug 3, 2026 and announced leadership changes.